Myeloproliferative Neoplasms Clinical Trial
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Summary
RATIONALE: Imatinib mesylate and interferon alfa may interfere with the growth of the cancer cells. Combining imatinib mesylate with interferon alfa may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining imatinib mesylate with interferon alfa in treating patients who have chronic myelogenous leukemia.
Full Description
OBJECTIVES:
Determine the maximum tolerated dose of interferon alfa administered with imatinib mesylate in patients with chronic phase chronic myelogenous leukemia. (Phase I closed to accrual as of 7/9/03.)
Determine the safety and tolerability of this regimen in this patient population.
Determine the complete, major, and minor cytogenetic response rates and complete hematologic response rate in patients after 6 and 12 months of treatment with this regimen.
Determine the molecular response (reverse transcriptase-polymerase chain reaction for bcr-abl) rate in patients who have a complete cytogenetic response after 6 and 12 months of treatment with this regimen.
Determine the pharmacokinetics of this regimen in these patients.
OUTLINE: This is a dose-escalation, multicenter study.
Phase I (closed to accrual as of 7/9/03): Patients receive oral imatinib mesylate once daily beginning on day 1 and interferon alfa (IFN-A) subcutaneously once daily or 3 times weekly beginning on day 14. Courses repeat every 35 days for up to 1 year in the absence of disease progression or unacceptable toxicity. After completion of 1 year of therapy, patients may receive additional therapy, provided that the patient is benefiting from imatinib mesylate. IFN-A is discontinued in patients who achieve a molecular remission that is confirmed on 2 successive bone marrow samples. Imatinib mesylate is discontinued in patients who achieve and maintain a molecular remission for 2 years.
Sequential dose escalation of IFN-A is followed by sequential dose escalation of imatinib mesylate. Cohorts of 3-6 patients receive escalating doses of IFN-A and then imatinib mesylate until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
Phase II: Patients receive imatinib mesylate and IFN-A as in phase I at the established MTD.
Patients are followed for 30 days.
PROJECTED ACCRUAL: Approximately 3-15 patients will be accrued for the phase I portion of this study. (Phase I closed to accrual as of 7/9/03.) A total of 40 patients will be accrued for the phase II portion of the study within 3-4 months.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Cytogenetically confirmed chronic myelogenous leukemia (CML)
Less than 15% blasts in peripheral blood or bone marrow
Less than 30% blasts and promyelocytes in peripheral blood or bone marrow
Less than 20% basophils in blood or bone marrow
Platelet count at least 100,000/mm^3
No leukemia beyond bone marrow, blood, liver, or spleen
No chloroma
Phase I (closed to accrual as of 7/9/03):
Philadelphia (Ph) chromosome-positive CML in chronic phase
Phase II:
Newly diagnosed Ph chromosome-positive CML in chronic phase
Initial diagnosis within 6 months of study
No prior therapy for CML except hydroxyurea and/or anagrelide hydrochloride
Phase I (closed to accrual as of 7/9/03) and II:
No identified sibling donors where allogeneic stem cell transplantation is elected as first-line therapy
PATIENT CHARACTERISTICS:
Age:
18 and over
Performance status:
ECOG 0-2
Life expectancy:
Not specified
Hematopoietic:
See Disease Characteristics
Hepatic:
Bilirubin no greater than 1.5 times upper limit of normal (ULN)
AST or ALT no greater than 2 times ULN
Renal:
Creatinine no greater than 1.5 times ULN
Cardiovascular:
No New York Heart Association class III or IV heart disease
Other:
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use 2 methods of effective barrier contraception during and for at least 3 months after study participation
No other serious uncontrolled medical condition
No autoimmune disease
No prior noncompliance to medical regimens or potential unreliability
No prior grade 3 or greater non-hematologic toxicity due to prior interferon (phase I [closed to accrual as of 7/9/03])
PRIOR CONCURRENT THERAPY:
Biologic therapy:
See Disease Characteristics
No prior bone marrow or peripheral blood stem cell transplantation
At least 2 weeks since prior interferon alfa (phase I [closed to accrual as of 7/9/03])
Chemotherapy:
See Disease Characteristics
At least 6 weeks since prior busulfan (phase I [closed to accrual as of 7/9/03] )
At least 2 weeks since prior cytarabine (phase I [closed to accrual as of 7/9/03])
No concurrent chemotherapy
Concurrent hydroxyurea allowed during the first 3 months of study
Endocrine therapy:
Not specified
Radiotherapy:
Not specified
Surgery:
Not specified
Other:
At least 4 weeks since prior investigational agents other than imatinib mesylate (phase I [closed to accrual as of 7/9/03])
No concurrent grapefruit juice
Concurrent anagrelide hydrochloride allowed during the first 3 months of study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Chicago Illinois, 60611, United States
Portland Oregon, 97239, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.